Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate

Contraception

Volumn 68, Issue 5, 2003, Pages 339-343

  Beksinska, Mags E ^a   Smit, Jenni A ^a   Kleinschmidt, Immo ^b   Rees, Helen V ^a   Farley, Tim M M ^c   Guidozzi, Franco ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Depomedroxyprogesterone acetate; Follicle stimulating hormone; Menopause; Norethisterone enanthate

Indexed keywords

FOLLITROPIN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; CONCENTRATION (PARAMETERS); CONTRACEPTION; CONTROLLED STUDY; DRUG EFFECT; FOLLITROPIN BLOOD LEVEL; HUMAN; INJECTION; LONG TERM CARE; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUAL CYCLE; NORMAL HUMAN; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE;

EID: 0242573042     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.08.003     Document Type: Article

References (12)

1. World Health Organisation Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone enanthate given in two dosage regimens and depot medroxyprogesterone acetate: Final report. Contraception 1983;23:1-20.
2. Guilleband J. Contraception: your questions answered. 1993;Churchill Livingstone, Edinburgh. p. 280.
3. Mishell D.R., Kharma K.M., Thorneycroft I.H., Nakamura R.M. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynaecol. 113:1972;3726.
4. Franchimont P., Cession G., Ayalon D., Musters A., Legros J.J. Suppressive action of norethisterone enanthate and depo medroxyprogesterone acetate on gonadotropin levels. Obstet Gynecol. 36:1970;93-100.
5. Fotherby K., Howard G., Srimanker K., Elder M., Bye P.G. Effect of norethisterone oenanthate on serum gonadotrophin levels. Contraception. 16:1977;591-604.
6. Perez-Palacois G., Chavez B., Escobar N., et al. Mechanism of action of contraceptive synthetic progestins. J Steriod Biochem. 15:1981;125-130.
7. Department of Health South Africa and Macro International. The South African Demographic and Health Survey, 1998. Preliminary report. Department of Health Pretoria, 1999.
8. Mishell D.R. Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 41:1996;381-390.
9. Fotherby K., Saxena B.N., Shrimanker K., et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot medroxyprogesterone acetate and norethisterone oeanthate. Fertil Steril. 34:1980;131-138.
10. Mckinley S.M., Brambilla D.J., Posner J.G. The normal menopause transition. Maturitus. 14:1992;103-115.
11. Sherman B.M., Korenman S.G. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest. 55:1975;699-706.
12. Burger G.H. Diagnostic role of follicle-stimulation hormone (FSH) measurements during the menopausal transition. An analysis of FSH, oestradiol and inhibin. Eur J Endrocrinol. 130:1994;38-42.